Due to the 2.03-fold increase in IGF2AS in estrogen-dependent breast cancer cells after CCT137690 treatment, we hypothesized that CCT137690 may suppress invasion and metastasis in the early stages of tumorigenesis. This evidence concerns the gene IGF2-AS and breast carcinoma.